CD34 and acute myeloid leukemia: Second, our data supports previous studies suggesting that NPM1 mutations are secondary to other AML driver mutations acquired in an expanded pool of committed myeloid progenitors, perhaps CD34−, further supporting the CD34−/low phenotype of NPM1-mutated AML patients.